
About Coeptis Therapeutics
Coeptis Therapeutics (NASDAQ:COEP) is a dynamic biotechnology firm dedicated to developing innovative treatments aimed at addressing unmet medical needs in various therapeutic areas. The company is traded exclusively on the NASDAQ stock exchange under the ticker code (NASDAQ:COEP), highlighting its focus on delivering cutting-edge healthcare solutions. Coeptis Therapeutics engages in a range of projects, from early-stage research to advanced clinical trials, aiming to pioneer new treatments that can dramatically improve patient outcomes. With a commitment to excellence and innovation, the company's primary objectives include advancing its current drug development programs, securing strategic partnerships, and expanding its pipeline with high potential therapeutic candidates. Through these efforts, Coeptis Therapeutics strives to make a significant impact in the medical field, bringing hope and new opportunities to patients around the globe.
Snapshot
Operations
Products and/or services of Coeptis Therapeutics
- Development of CD38-targeted autologous CAR-T cell therapy for multiple myeloma.
- Advancing SNAP-CAR platform for generating universal CAR-T cells with enhanced safety and efficacy.
- Development of G1T38, an oral CDK4/6 inhibitor for breast cancer treatment.
- Commercial partnership for distributing novel oncology therapies in specific markets.
Coeptis Therapeutics executive team
- Mr. David MehalickCo-Founder, Chairman of the Board, CEO & President
- Ms. Christine Elise SheehyCo-Founder and VP of Compliance & Corporate Secretary
- Mr. Daniel Alexander YeraceCo-Founder, VP of Operations & Director
- Mr. Brian Cogley M.B.A.Chief Financial Officer